Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_assertion description "[Furthermore, in a cohort of patients with newly diagnosed RA, elevated PAR(2) expression in both CD14+ and CD3+ cells was significantly reduced 3 months after methotrexate or sulfasalazine treatment and this reduction correlated significantly with the reduction in the 28-joint Disease Activity Scale score (p<0.05).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_assertion evidence source_evidence_literature NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_assertion SIO_000772 22294633 NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_assertion wasDerivedFrom befree-2016 NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_assertion wasGeneratedBy ECO_0000203 NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.
- befree-2016 importedOn "2016-02-19" NP957632.RAbjjeiPfQUK_lcrww0QZbz4wEwNiDV6JUrA6-LgqMUaU130_provenance.